Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  439 results for ""Oxazines""

Your Filters

Subject : hiv integrase inhibitors
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics.

Subjects: Pyridones* ; Oxazines* ; Piperazines*

  • Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Oct; Vol. 116 (4), pp. 1100-1109. Date of Electronic Publication: 2024 Jul 16.Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535

Record details

Read More Add to Saved list
×
Academic Journal

HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST).

  • Authors : Egger M; Institute of Social & Preventive Medicine, University of Bern, Bern, Switzerland .; Centre for Infectious Disease Epidemiology and Research, University of Cape Town Faculty of Health Sciences, Cape Town, Western Cape, South Africa.

Subjects: Pyridones* ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/therapeutic use ; Oxazines*/Oxazines*/Oxazines*/therapeutic use

  • Source: BMJ open [BMJ Open] 2024 Aug 21; Vol. 14 (8), pp. e085819. Date of Electronic Publication: 2024 Aug 21.Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.

  • Authors : Beck IA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.; Boyce CL

Subjects: Oxazines* ; HIV-1*/HIV-1*/HIV-1*/genetics ; HIV-1*/HIV-1*/HIV-1*/drug effects

  • Source: Viruses [Viruses] 2024 Jul 19; Vol. 16 (7). Date of Electronic Publication: 2024 Jul 19.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915

Record details

Read More Add to Saved list
×
Academic Journal

Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.

Subjects: Pyridones* ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/administration & dosage ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/pharmacokinetics

  • Source: AIDS (London, England) [AIDS] 2024 Jul 15; Vol. 38 (9), pp. F11-F18. Date of Electronic Publication: 2024 May 17.Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

A preliminary study on plasma concentration, short-term efficacy, and safety profile of dolutegravir in Chinese people with HIV.

  • Authors : Li D; Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Subjects: Pyridones* ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/administration & dosage ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/adverse effects

  • Source: Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2024 Jul; Vol. 17 (7), pp. 625-631. Date of Electronic Publication: 2024 Jan 26.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278296 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection.

  • Authors : Kress TC; Vascular Biology Center, Medical College of Georgia at Augusta University,United States of America.; Ajala P

Subjects: Energy Metabolism*/Energy Metabolism*/Energy Metabolism*/drug effects ; Mice, Transgenic* ; Piperazines*/Piperazines*/Piperazines*/pharmacology

  • Source: Vascular pharmacology [Vascul Pharmacol] 2024 Jun; Vol. 155, pp. 107288. Date of Electronic Publication: 2024 Feb 28.Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130615 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.

  • Authors : Maphosa T; Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi. .; Dunga S

Subjects: Pyridones* ; HIV Infections*/HIV Infections*/HIV Infections*/drug therapy ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/therapeutic use

  • Source: BMC public health [BMC Public Health] 2024 May 16; Vol. 24 (1), pp. 1321. Date of Electronic Publication: 2024 May 16.Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458

Record details

Connect Read More Add to Saved list
×
Academic Journal

Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy.

  • Authors : Hurbans N; Discipline of Pharmaceutical Sciences, School of Health Sciences, College of Health Science, University of KwaZulu-Natal, Westville, Durban, South Africa.; South African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.

Subjects: Pyridones*/Pyridones*/Pyridones*/administration & dosage ; Oxazines* ; HIV Infections*/HIV Infections*/HIV Infections*/drug therapy

  • Source: The Pan African medical journal [Pan Afr Med J] 2024 Mar 25; Vol. 47, pp. 137. Date of Electronic Publication: 2024 Mar 25 (Print Publication: 2024).Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study.

  • Authors : Hurbans N; Discipline of Pharmaceutical Sciences, School of Health Sciences, College of Health Science, University of KwaZulu-Natal, Westville, Durban, 4001, South Africa. .; South African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa. .

Subjects: HIV Infections*/HIV Infections*/HIV Infections*/drug therapy ; HIV Integrase Inhibitors*/HIV Integrase Inhibitors*/HIV Integrase Inhibitors*/adverse effects ; Oxazines*

  • Source: BMC infectious diseases [BMC Infect Dis] 2024 Mar 21; Vol. 24 (1), pp. 343. Date of Electronic Publication: 2024 Mar 21.Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.

  • Authors : Chu C; Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA 94110, USA.; Tao K

Subjects: HIV Infections*/HIV Infections*/HIV Infections*/drug therapy ; HIV Infections*/HIV Infections*/HIV Infections*/epidemiology ; HIV Integrase Inhibitors*/HIV Integrase Inhibitors*/HIV Integrase Inhibitors*/therapeutic use

  • Source: Viruses [Viruses] 2024 Mar 04; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 04.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915

Record details

Read More Add to Saved list
×
  • 1-10 of  439 results for ""Oxazines""